According to Baveno VII, how should variceal screening and primary prophylaxis be managed in patients with compensated cirrhosis?

Baveno VII Variceal Screening and Primary Prophylaxis in Compensated Cirrhosis

In patients with compensated cirrhosis, use non-invasive criteria (liver stiffness measurement <20 kPa AND platelets >150,000/µL) to safely avoid screening endoscopy, and treat all patients with clinically significant portal hypertension (CSPH) with non-selective beta-blockers regardless of variceal size to prevent both bleeding and non-bleeding decompensation. 1

Non-Invasive Screening Strategy

The Baveno VII consensus fundamentally shifted the paradigm from screening for varices to screening for CSPH, recognizing that beta-blockers prevent all forms of decompensation, not just variceal bleeding 1.

When to Avoid Endoscopy (Rule Out High-Risk Varices)

• Liver stiffness <20 kPa AND platelets >150,000/µL: These patients can safely avoid screening endoscopy as high-risk varices are effectively ruled out 1
• Liver stiffness <12 kPa AND platelets >150,000/µL: CSPH can be ruled out entirely in these patients 1

When Endoscopy is Required

• Liver stiffness ≥20 kPa OR platelets <150,000/µL: Perform endoscopy if not already on non-selective beta-blockers 1
• Liver stiffness 20-25 kPa OR platelets <150,000/µL: CSPH is probable; endoscopy indicated for those not on therapy 1
• Liver stiffness >25 kPa: CSPH is highly likely (rule-in criteria); may start non-selective beta-blockers empirically without endoscopy, though endoscopy can be performed if treatment decision depends on variceal presence 1, 2

Critical CSPH subgroup: Patients with liver stiffness 50-75 kPa have approximately double the risk of decompensation and death compared to those with 25-49.9 kPa, warranting particularly aggressive management 2.

Surveillance Intervals for Endoscopy

When endoscopy is performed, surveillance frequency depends on initial findings and compensation status 1:

Compensated Cirrhosis

• No varices: Repeat endoscopy every 2-3 years 1
• Small varices: Repeat endoscopy every 1-2 years 1

Decompensated Cirrhosis

• Any finding: Repeat endoscopy annually 1

Primary Prophylaxis Strategy

For Patients with CSPH (Any Size Varices)

All patients with CSPH should receive non-selective beta-blockers to prevent both variceal bleeding and non-bleeding decompensation events (such as ascites) 1. This represents a major shift from previous guidelines that only treated medium/large varices.

Treatment Options Based on Variceal Size

Small varices with CSPH: Non-selective beta-blockers are preferred 1

Medium or large varices:

• Non-selective beta-blockers are the preferred first-line therapy in compensated patients, as they significantly improve survival compared to endoscopic variceal ligation (EVL) 3
• EVL is an acceptable alternative but shows inferior survival benefit in compensated cirrhosis 3
• Combination therapy (beta-blockers + EVL) does not provide additional survival benefit over beta-blockers alone in compensated patients 3

Decompensated patients: Both non-selective beta-blockers and EVL show similar efficacy; either can be used 3

Variceal Classification

Varices should be classified simply as small or large with a 5 mm cutoff 1:

• Small varices: Minimally elevated veins above esophageal mucosa, <5 mm diameter
• Large varices: >5 mm diameter, or occupying >1/3 of esophageal lumen when using 3-grade classification 1
• Document presence of red signs (red wale marks or spots) as these indicate higher bleeding risk 1

Special Considerations

Patients already on beta-blockers: Screening endoscopy can be avoided in patients already taking non-selective beta-blockers for other indications (e.g., hypertension) 1

Gastric varices: GOV1 (extending along lesser curvature) should be managed like esophageal varices; IGV1 (fundal varices) require exclusion of splenic vein thrombosis 1

Common Pitfalls to Avoid

• Do not use Baveno criteria in HCC patients: These criteria may not adequately exclude high-risk varices in patients with hepatocellular carcinoma; endoscopy should still be performed unless liver stiffness ≥25 kPa 4
• Do not delay treatment in high-risk patients: Patients with liver stiffness >25 kPa can be started on non-selective beta-blockers without waiting for endoscopy 1
• Do not use selective beta-blockers: Patients on selective beta-blockers (metoprolol, atenolol) should be switched to non-selective agents (propranolol, nadolol, carvedilol) 1
• Beta-blockers only work with CSPH: Non-selective beta-blockers are only effective when hyperdynamic circulation is present (HVPG >10 mmHg), so they should not be used in patients without CSPH 1